OMass Therapeutics
OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.
$310MSeries C
ParticipantSV
Sanofi Ventures
Activity from announced rounds
Activity in this selectionOct 17, 2026 · Jul 20, 2026
- Rounds participated in
- 4
- Confirmed lead rounds
- 0 3 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $511M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionAbcuro
Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease.
$66MSeries D
Role not disclosedEpicrispr Biotechnologies
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
$90MSeries C
Role not disclosedQuantHealth
AI-driven platform that simulates clinical trials to predict outcomes before patient enrollment
$45MSeries B
Role not disclosed